{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not estimable","groupId":"OG000","lowerLimit":"34","upperLimit":"NA","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Time elapsed between Day 0 and disease progression, as defined by the International Myeloma Working Group (IMWG) disease response criteria. Disease progression is defined as an increase of \\>25% from lowest response value in any one or more of the following:\n\n* Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL)\n* Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h)\n* Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved free light chain levels. The absolute increase must be \\> 10 mg/dL\n* Bone marrow plasma cell percentage; the absolute percentage must be \\> 10%\n* Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 225 mg/m\\^2 total, Melphalan 200 mg/m\\^2 total (140 mg/m\\^2 total for patients with Creatinine Clearance \\<70 ml/min)","id":"OG000","title":"Phase 2"}],"paramType":"MEDIAN","populationDescription":"Phase 2 includes all patients treated on phase 2 of the study (28 patients), and patients treated at Dose Level 6 of the Phase 1 portion of the study (7 patients). The dose level used during Phase 2 was Dose Level 6.","reportingStatus":"POSTED","timeFrame":"From Day 0 to first incidence of disease progression, up to 86 months","title":"Progression-Free Survival (Phase 2)","type":"SECONDARY","unitOfMeasure":"Months"}